What is new in iPrEx?
A new PrEP Study
Recruiting participants in England
• • • • • •
VOICE Results
Confirm that PrEP is Effective...
• • • • • •
Pilot demostration and Evaluation Project HIV-1
The Partners Demonstration Project
• • • • • •
ATN launches the PrEPare study
14 sites in the US are making part
• • • • • •
ANRS-IPERGAY study should be discontinued
prevention research in France is in disarray
• • • • • •
The Anrs decides to continue its Ipergay trial
And creates a new working group on HIV prevention
• • • • • •
Truvada aprobada en Ecuador
Para tratamiento de infección por VIH
• • • • • •
San Francisco AIDS Foundation (SFAF) launched a PrEP Information Site
To provide community information
• • • • • •
SFDPH launched Demo Project of PrEP
To evaluate the delivery of PrEP in STD clinics
• • • • • •
PrEP Interim Guidance for PrEP in Sexually Active Heterosexual Adults
• • • • • •
WHO issues first PrEP guidance
After FDA approved Truvada for PrEP
• • • • • •
HPTN Launches NEXT-PrEP Trial
The study will evaluate Maraviroc
• • • • • •
Truvada approved for HIV prevention
• • • • • •
The iPrEx Study Closed Enrollment in OLE
Follow up will end in February of 2014
• • • • • •
ad-hoc-PrEP Group Southern African guidelines
For the safe use of pre-exposure prophylaxis in MSM
• • • • • •
BBC News: Interview with Robert Grant.
PrEP and its potential after FDA Advisory Committee Meeting
• • • • • •
AVDAC Recommends FTC/TDF
For the prevention of HIV infection in adults as PrEP
• • • • • •
iPrEx and the Supplemental New Drug Application of Truvada for PrEP
• • • • • •
AIDS Advocates Support FDA Approval of PrEP
Urgent Need of New HIV Prevention Tools to End AIDS
• • • • • •
UC will test HIV prevention pills
• • • • • •
FDA finalizes Audits at Global iPrEx in South America
No critical issues in the implementation of the study.
• • • • • •
FDA performs visit inspection to the Ecuador site
To check the conduction of the Global iPrEx
• • • • • •
Truvada Priority Review
U.S.Food and Drug Administration (FDA)
• • • • • •
Launch of first pre-HIV exposure prevention trial for gay men in Europe
IPERGAY is a French ANRS initiative
• • • • • •
FDA asked to approve NEW HIV PREVENTION METHOD
Gilead submitted supplemental New Drug Application (sNDA)
• • • • • •
Bob Grant People who Mattered in 2011
• • • • • •
VOICE DSMB Recommends Stopping Tenofovir Gel Arm
NIAID has made a public announcement on November 25, 2011
• • • • • •
iPrEx OLE: 279 additional participants
CDC Project T will Join the study
• • • • • •
Unblinding iPrEx
iPrEx study sites have been unblinding participants since June of 2011
• • • • • •
PrEP Demonstration Projects about to be Launched
San Francisco will be the first city in the United States
• • • • • •
6th IAS Conference
New data confirm eficacy and safety of PrEP
• • • • • •
iPrEx OLE begins at 11 sites in six countries
iPrEx OLE to Build on News that PrEP Slows HIV Infections
• • • • • •
News on Partners PrEP and CDC Botswana
Studies detailing the safety and effectiveness of PrEP
• • • • • •
The FACTS 001 tenofovir gel study
• • • • • •
Intermittent PrEP
• • • • • •
30 years into the epidemic
• • • • • •
News on HPTN 052
Another HIV Prevention Trial Shows Success
• • • • • •
News on FEM-PrEP
FEM-PrEP trial is stopped by the IDMC
• • • • • •
CROI 2011
iPrEx presented new data in the conference in Boston
iPrEx CROI release
• • • • • •
US Centers for Disease Control and Prevention (CDC)
iPrEx es un ensayo clínico cuyo objetivo es evaluar si dos medicamentos antiretrovirales (ARV), usados para tratar el VIH/SIDA ayudan a prevenir la adquisición de VIH en personas no infectadas con VIH en alto riesgo de infección